Vitamin D receptor has antiproliferative effects in pulmonary arterial hypertension, but receptor expression is downregulated ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Presentations at the 2024 Asembia Specialty Pharmacy Summit focused on reshaping specialty pharmacy while keeping patients ...

Royalty Corporation now owns an economic interest in seralutinib, a Phase 3 asset being studied in pulmonary arterial hypertension ...

XOMA Royalty Corp. (XOMA), a biotechnology royalty aggregator, Monday announced that it now owns royalty and milestone interest in ...

Seralutinib is being developed and co-commercialized by Gossamer Bio, Inc., and Chiesi Farmaceutici S.p.A; a Phase 3 study for pulmonary arterial hypertension is ongoing and is expected to read out in ...

Two industry-sponsored studies investiaged needs of people with pulmonary hypertesion and interstitial lung disease.

HETE is the endogenous agonist for G protein-coupled receptor 39 (GPR39) in vascular smooth cells, so researchers ...

especially those people who have underlying chronic lung disease Pulmonary hypertension is a condition where the blood ...

When frostbitten limbs warm up again, blood rushes back into the tissue. With that blood come compounds such as histamines ...

Winrevair lowered death or transplant risk in adults with PAH functional class 3-4 at high risk of dying; all in study may ...

The study was stopped early to allow all patients with advanced PAH the option for treatment with the activin signaling ...